ArticleDiscover oncology2025
Ubiquitin-specific protease 34 serves as a novel prognostic biomarker through correlating with immune responses and cell proliferation in acute myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Associations of Tumor Somatic Mutations and Genetic Alterations with Survival Outcomes in Melanoma Patients Treated with Ipilimumab.Journal of clinical medicine · 2026Article
- The deubiquitinase USP35: from an oncogenic hub to a therapeutic target in human cancers.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundEmerging evidence showed that ubiquitin-specific proteases (USPs) are promising therapeutic targets for hematopoietic malignancies. The roles of USP34 on acute myeloid leukemia (AML) pathogenesis remain completely unknown.
methodsGene expression and prognostic relevance were analyzed utilizing public AML datasets from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), and validated with the Gene Expression Profiling Interactive Analysis (GEPIA), BloodSpot and the human protein atlas (HPA) databases. Systematical analyses are performed to characterize the immune infiltration and biological function of USP34 in AML. MTS, colony formation and EdU assays were also employed to confirm the effect of USP34 on cell proliferation in AML cells.
resultsUSP34 expression was significantly higher in AML compared to its matched normal samples. Higher USP34 expression predicted worse prognosis in AML, and USP34 acted as an independent prognostic predictor for AML patients (HR:1.365, 95%CI:1.032-1.805, p = 0.029). Moreover, the expression of USP34 was associated with several immune cells, including Treg cells, indicating its potential role in modulating immune responses. Finally, functional experiments revealed that USP34 knockdown reduced cell proliferation in Molm-13 and Kasumi cells.
conclusionsUSP34 is an independent prognostic predictor in AML and may contribute to leukemogenesis via intervening immune processes and promoting proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.